BioStock: Phase I is approaching for Dicot

Many follow Dicot’s development with eager anticipation. After this winter’s share issue, the company now announce good results from the completed toxicological program. The phase I clinical trial is expected to start in August. BioStock contacted Dicot’s CEO Elin Trampe to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/05/phase-i-is-approaching-for-dicot/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se